Abstract
The current study observes that while several studies have been conducted on the direct-to-consumer advertising (DTCA) of prescription drugs, none has explicitly evaluated the ethical dimension DTCA of prescriptions, as such a knowledge gap still exists with regard to the ethics of DTCAs. To contribute to filling this gap, the current study evaluates the ethical DTCA of prescription drugs using Pfizer’s Lipitor ad, which because of public outcry, was terminated shortly after it was launched. The study concludes that what may be legal may not necessarily be ethical. Thus marketing decision marketers must expand their focus group testing of DTCAs to include assessment of their ethics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
